Premium
Two distinct human myeloma cell lines originating from one patient with myeloma
Author(s) -
Katagiri Shuichi,
Yonezawa Takeshi,
Kuyama Jun,
Kanayama Yoshio,
Tamakl Toshiharu,
Ohnishi Mitsunobu,
Tarui Seiichiro,
Nishida Kazuhiro,
Abe Tatsuo
Publication year - 1985
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910360217
Subject(s) - cell culture , antibody , immunoglobulin light chain , multiple myeloma , monoclonal antibody , phenotype , biology , subclass , doubling time , cytoplasm , receptor , microbiology and biotechnology , immunology , genetics , gene
Two distinct cell lines (OPM‐l and OPM‐2) were established from the peripheral blood of a 56‐year‐old female myeloma patient at the stage of terminal leukemic evolution associated with loss of cytoplasmic immunoglobulin heavy chain (Gλ ± λ). The lines grew in suspension with a doubling time of 36‐42 hr and 30‐36 hr, respectively. EBNA was absent from both lines. The lines synthesized cytoplasmic λ‐chain, but had no detectable surface immunoglobulins. Fc receptors and complement receptors could not be detected in either line. The lines had very complex chromosomal abnormalities, but the patterns of chromosomes differed greatly between the two lines. The two lines, together with the RPMI 8226 line established by Matsuoka et al . (1967), were analyzed for phenotypic expression as defined by a panel of monoclonal antibodies to B cells (B1, BA‐1, BA‐2, BA‐3, OKla‐1 and OKT10/BMA0100). Neither OPM‐I nor OPM‐2 reacted with any of the antibodies tested except OKT10. OPM‐l cells reacted weakly ( < 30%) with OKT10/BMA0100, while OPM‐2 cells showed a fluctuating reactivity, ranging from 40 to 80%, with OKT10/BMA0100. In contrast, RPMI 8226 reacted strongly with OKT10 and BA‐2. These results demonstrate the presence of phenotypic heterogeneity in all 3 myeloma cell lines, suggesting that the lines might represent different stages of terminal B‐cell development.